Lyka Labs Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Lyka Labs hat ein Gesamteigenkapital von ₹682.7M und eine Gesamtverschuldung von ₹587.8M, wodurch sich der Verschuldungsgrad auf 86.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₹1.6B bzw. ₹884.6M. Lyka Labs Das EBIT des Unternehmens beträgt ₹57.5M, so dass der Zinsdeckungsgrad 1.8 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₹62.9M.

Wichtige Informationen

86.1%

Verhältnis von Schulden zu Eigenkapital

₹587.80m

Verschuldung

Zinsdeckungsgrad	1.8x
Bargeld	₹62.92m
Eigenkapital	₹682.65m
Gesamtverbindlichkeiten	₹884.59m
Gesamtvermögen	₹1.57b

Jüngste Berichte zur Finanzlage

We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt

Nov 21

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively

Jun 08

Is Lyka Labs (NSE:LYKALABS) A Risky Investment?

Jun 11

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Feb 21

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Nov 03

Recent updates

There's Reason For Concern Over Lyka Labs Limited's (NSE:LYKALABS) Massive 36% Price Jump

Aug 22

Shareholders May Be More Conservative With Lyka Labs Limited's (NSE:LYKALABS) CEO Compensation For Now

Aug 03

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively

Jun 08

A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS)

Mar 15

Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares

Aug 25

Is Lyka Labs (NSE:LYKALABS) A Risky Investment?

Jun 11

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Feb 21

Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are

Nov 05

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Nov 03

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: LYKALABSDie kurzfristigen Aktiva des Unternehmens (₹506.5M) übersteigen seine kurzfristigen Passiva (₹376.4M).

Langfristige Verbindlichkeiten: LYKALABSDie kurzfristigen Vermögenswerte des Unternehmens (₹506.5M) decken seine langfristigen Verbindlichkeiten (₹508.2M) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: LYKALABSDie Nettoverschuldung im Verhältnis zum Eigenkapital (76.9%) wird als hoch angesehen.

Schulden abbauen: LYKALABS Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 219.6% auf 86.1% zurückgegangen.

Schuldendeckung: LYKALABSDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (3%) gedeckt.

Zinsdeckung: LYKALABSDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (1.8x Deckung) nicht gut gedeckt.

Lyka Labs Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively

Is Lyka Labs (NSE:LYKALABS) A Risky Investment?

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Recent updates

Lyka Labs Limited to Report Q2, 2025 Results on Nov 12, 2024

There's Reason For Concern Over Lyka Labs Limited's (NSE:LYKALABS) Massive 36% Price Jump

New minor risk - Share price stability

Shareholders May Be More Conservative With Lyka Labs Limited's (NSE:LYKALABS) CEO Compensation For Now

Lyka Labs Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings released: ₹0.79 loss per share (vs ₹4.63 loss in FY 2023)

Lyka Labs Limited, Annual General Meeting, Aug 09, 2024

Lyka Labs Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings released: ₹0.79 loss per share (vs ₹4.63 loss in FY 2023)

Lyka Labs Limited to Report Q4, 2024 Results on May 21, 2024

Getting In Cheap On Lyka Labs Limited (NSE:LYKALABS) Is Unlikely

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: ₹0.53 (vs ₹3.64 loss in 3Q 2023)

Lyka Labs Limited to Report Q3, 2024 Results on Feb 08, 2024

Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price

We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt

Second quarter 2024 earnings released: ₹0.16 loss per share (vs ₹0.14 loss in 2Q 2023)

Lyka Labs Limited to Report Q2, 2024 Results on Nov 02, 2023

Lyka Labs Limited Receives Product Permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w

Lyka Labs Limited Announces Cessation of Sandeep Parikh as Independent Director

Lyka Labs Limited to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings released: ₹4.63 loss per share (vs ₹13.56 profit in FY 2022)

Lyka Labs Limited, Annual General Meeting, Aug 02, 2023

Lyka Labs Limited, Annual General Meeting, Aug 02, 2023

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively

Full year 2023 earnings released: ₹4.63 loss per share (vs ₹13.56 profit in FY 2022)

Lyka Labs Limited to Report Q4, 2023 Results on May 23, 2023

A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS)

Third quarter 2023 earnings released: ₹3.64 loss per share (vs ₹2.11 profit in 3Q 2022)

Lyka Labs Limited to Report Q3, 2023 Results on Feb 07, 2023

Less than half of directors are independent

Second quarter 2023 earnings released: ₹0.14 loss per share (vs ₹9.90 profit in 2Q 2022)

Lyka Labs Limited to Report Q2, 2023 Results on Nov 09, 2022

High number of new directors

Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares

Investor sentiment improved over the past week

Lyka Labs Limited Announces Board Appointments

Lyka Labs Limited Announces Resignation of Smt. Nehal N. Gandhi as Director with Effect from August 8, 2022

Lyka Labs Limited Announces Cessation of Vinod S. Shanbhag as Independent Director

Full year 2022 earnings released: EPS: ₹13.57 (vs ₹4.07 loss in FY 2021)

Is Lyka Labs (NSE:LYKALABS) A Risky Investment?

Full year 2022 earnings released: EPS: ₹13.57 (vs ₹4.07 loss in FY 2021)

Lyka Labs Limited, Annual General Meeting, Aug 05, 2022

Lyka Labs Limited to Report Q4, 2022 Results on May 20, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

High number of new directors

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

High number of new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are

These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well

Second quarter 2022 earnings released: EPS ₹9.90 (vs ₹2.01 loss in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: ₹4.07 loss per share (vs ₹21.29 loss in FY 2020)

Lyka Labs Limited Announces Information Regarding Manufacture and Market of Liposomal Amphotericin B Injection

Full year 2021 earnings released: ₹4.07 loss per share (vs ₹21.29 loss in FY 2020)

Third quarter 2021 earnings released: ₹0.80 loss per share (vs ₹14.50 loss in 3Q 2020)

Lyka Labs Limited to Report Q3, 2021 Results on Feb 11, 2021

New 90-day high: ₹25.60

Second quarter 2021 earnings released: ₹2.01 loss per share

Lyka Labs Limited Announces Resumption of Operations

First quarter earnings released